Oklo’s Lower Price Target Still Requires Investors to Fund the Wait

Barclays cut its Oklo price target to $59 from $76 on October 20 but kept an Overweight rating. With Oklo closing at $27.24 on October 19, the revised target still implied roughly 117% upside. That large gap says more about the uncertainty around Oklo’s future cash flows than it does about near-term operating performance.

Oklo is still an early commercial-stage nuclear developer. Its second-quarter filings showed $3.0 billion of cash and marketable securities at June 30, including about $1.9 billion raised through at-the-market share sales during the first half of 2026. The same filings showed $126.9 million of capital expenditures and an $81.6 million net loss for the first six months.

That combination gives the company substantial liquidity, but it also illustrates the financing tradeoff. Equity sales reduce near-term funding risk while increasing the share count. Oklo established additional at-the-market capacity in September, leaving investors exposed to further dilution if spending remains high before commercial power revenue arrives.

Operational progress is real but incomplete. Oklo’s Groves isotope reactor in Texas reached first criticality in August, while the company continued work on its Aurora project at Idaho National Laboratory. Those milestones demonstrate engineering progress. They do not yet establish the economics, construction schedule or recurring revenue of a fleet-scale power business.

The valuation is difficult to anchor because current revenue is small relative to the capital required. Barclays’ target depends on investors assigning value to projects years before they generate material cash flow. Higher long-term interest rates make that future value less attractive today, and any delay can increase both the financing need and the dilution risk.

The next quarterly report should be judged less by conventional earnings and more by three questions: whether Aurora remains on schedule, whether project costs are tracking within guidance, and whether the company can convert development agreements into binding revenue contracts. A stronger cash balance buys time, but it does not remove execution risk. Until Oklo shows that its first commercial plants can move from development to financed construction, a $59 target remains a scenario rather than a conclusion.